+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Destruction of the Suprachiasmatic Nuclei on the Circadian Rhythms in Plasma Corticosterone, Body Temperature, Feeding and Plasma Thyrotropin

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To study the role of the suprachiasmatic nuclei (SCN) in generating circadian rhythms in female rats, lesions were placed in the SCN or in the medial preoptic (PO) region. Serial blood sampling at 4-hour intervals at 3 and 13 weeks after surgery indicated that complete SCN destruction abolished rhythmic fluctuations in plasma corticosterone levels in individual rats. Partial destruction produced less interference, while medial PO lesions that spared the SCN were without effect. Similar effects were noted on daily changes in body temperature at 10 weeks after surgery; however, some rats showed evidence of dissociation of these two rhythmic functions in that some lesions appeared to affect one and not the other. In ancillary studies, it was found that all lesioned groups showed nocturnal feeding patterns similar to those of the controls and that the diurnal pattern in plasma thyrotropin (TSH) levels was altered by complete destruction of the SCN. These data suggest that the SCN are essential for the circadian rhythms in pituitary-adrenal function and body temperature and that separate pacemakers may be present in these nuclei for these two periodic functions. The SCN may also control rhythmic TSH secretion, but these nuclei and the medial PO region do not appear essential for nocturnal feeding.

          Related collections

          Author and article information

          S. Karger AG
          26 March 2008
          : 29
          : 2
          : 119-131
          Departments of Anatomy and Medicine, University of Oregon Health Sciences Center, Portland, Oreg.
          122913 Neuroendocrinology 1979;29:119–131
          © 1979 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 13
          Original Paper


          Comment on this article